{
    "Trade/Device Name(s)": [
        "Tina-quant Cystatin C Gen.2",
        "Cystatin C Gen.2"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K161817",
    "Predicate Device Reference 510(k) Number(s)": [
        "K141143"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NDY"
    ],
    "Summary Letter Date": "June 27, 2016",
    "Summary Letter Received Date": "July 1, 2016",
    "Submission Date": "June 24, 2016",
    "Regulation Number(s)": [
        "21CFR862.1225"
    ],
    "Regulation Name(s)": [
        "Creatinine test system",
        "Cystatin C test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Cystatin C"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Li-heparin tube",
        "K2-EDTA tube",
        "K3-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Roche/Hitachi cobas c systems",
        "Roche/Hitachi cobas c 501"
    ],
    "Method(s)/Technology(ies)": [
        "Particle enhanced immunoturbidimetric assay",
        "Immunoturbidimetry"
    ],
    "Methodologies": [
        "Quantitative immunoturbidimetry"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Tina-quant Cystatin C Gen.2, a modified immunoturbidimetric assay for quantitative determination of cystatin C in human serum and plasma",
    "Indications for Use Summary": "In vitro test for quantitative determination of cystatin C in human serum and plasma on Roche/Hitachi cobas c systems, used as an aid in the diagnosis and treatment of renal diseases",
    "fda_folder": "Clinical Chemistry"
}